BioNTech (NASDAQ:BNTX) Stock Price Down 0.9% – Here’s Why

BioNTech SE (NASDAQ:BNTX) dropped 0.9% on Friday . The stock traded as low as $117.79 and last traded at $119.58. Approximately 226,396 shares were traded during trading, a decline of 72% from the average daily volume of 814,359 shares. The stock had previously closed at $120.72.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on BNTX shares. UBS Group increased their price target on shares of BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. cut their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research note on Tuesday. HSBC boosted their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. TD Cowen dropped their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Finally, Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Stock Down 1.9 %

The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a 50 day simple moving average of $113.69 and a two-hundred day simple moving average of $98.50. The company has a market capitalization of $28.38 billion, a PE ratio of -56.94 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same period last year, the firm posted $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. Research analysts expect that BioNTech SE will post -3.68 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after purchasing an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the last quarter. Blue Trust Inc. raised its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the last quarter. Gallacher Capital Management LLC grew its stake in BioNTech by 12.1% in the 2nd quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company’s stock valued at $294,000 after acquiring an additional 395 shares during the last quarter. Finally, TD Asset Management Inc increased its holdings in BioNTech by 6.1% during the 2nd quarter. TD Asset Management Inc now owns 7,590 shares of the company’s stock valued at $612,000 after acquiring an additional 435 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.